Skip to content
Evigrade
MajorNon-steroidal anti-inflammatory drugs, propionic acid derivatives×Calcineurin inhibitor (immunosuppressant)

Updated · Methodology

Mechanism

Tacrolimus can impair renal function on its own. Drugs with known nephrotoxic or neurotoxic effects, including non-steroidal anti-inflammatory drugs (NSAIDs), may potentiate these effects of tacrolimus (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dexketoprofen is an NSAID. Its SmPC states that NSAIDs may increase the nephrotoxicity of tacrolimus through effects mediated by renal prostaglandins (dexketoprofen SmPC, AEMPS). In renal impairment, NSAIDs can worsen renal function and cause fluid retention and oedema (dexketoprofen SmPC, AEMPS). Tacrolimus is more than 98.8% bound to plasma proteins and dexketoprofen 99%. The tacrolimus SmPC asks prescribers to consider possible interactions with other highly protein-bound drugs, including NSAIDs (AEMPS).

Symptoms

Tacrolimus very commonly impairs renal function and causes hyperkalaemia. Common reactions include oliguria and renal failure, including acute renal failure (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acute renal impairment from tacrolimus toxicity can show as high serum creatinine, hyperkalaemia, reduced urea excretion and hyperuricaemia, and is usually reversible (tacrolimus label, US Food and Drug Administration, FDA). Like all non-steroidal anti-inflammatory drugs, dexketoprofen can raise blood urea nitrogen and creatinine. It may be associated with renal adverse effects that can lead to glomerulonephritis, interstitial nephritis, renal papillary necrosis, nephrotic syndrome and acute renal failure (dexketoprofen SmPC, AEMPS).

Management

The combination is not contraindicated. The tacrolimus summary of product characteristics (SmPC) recommends avoiding tacrolimus with drugs that have known nephrotoxic effects and explicitly lists non-steroidal anti-inflammatory drugs (NSAIDs) among them. Dexketoprofen belongs to this class (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the combination cannot be avoided, closely monitor tacrolimus trough blood levels, renal function and other adverse effects. Adjust the tacrolimus dose if needed, and consider reducing it if nephrotoxicity occurs (AEMPS). Monitor renal function throughout combined use of dexketoprofen and tacrolimus (dexketoprofen SmPC, AEMPS). The US tacrolimus label says to monitor renal function and tacrolimus blood levels when tacrolimus is combined with other known nephrotoxic drugs. During concurrent use, adjust the dose of tacrolimus, the other drug or both (tacrolimus label, US Food and Drug Administration, FDA). Dexketoprofen is contraindicated at creatinine clearance below 59 mL/min. At 60–89 mL/min, reduce the starting dose to a total of 50 mg a day. Make sure fluid intake is adequate during treatment (dexketoprofen SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dexketoprofen

Other interactions with Tacrolimus